Dr Schnipper brings with him 20 years of experience in the clinical development of medicines for the pharmaceutical and biotechnology industries. He also took up responsibility for many clinical trial programs that resulted in development, approval and commercial growth for new therapeutic products in oncology and other therapeutic areas.
Before joining Bind Biosciences, Dr Schnipper has served as vice president of clinical development at Alza, where he was responsible for the clinical development for new pharmaceutical products, as well as the Phase IV strategies for products in its pharmaceutical product portfolio and pipeline.
Prior to Alza, Dr Schnipper was senior vice president and medical director at Sequus Pharmaceuticals, where he worked for clinical and regulatory functions and a member of the executive committee and lead FDA approval of Doxil (liposomal doxorubicin), a nanoparticle-based oncology drug . Prior to Sequus, he held various senior clinical positions at Hoffmann-La Roche.
Scott Minick, president and CEO of Bind Biosciences, said: “He has a track record in drug development, including being instrumental in directing the clinical trials that led to the FDA approval and successful commercial launch of the nanotechnology oncology drug, Doxil.
“Ed is qualified to lead our clinical team and also collaborate with the recently-formed board of clinical advisors for Bind Biosciences, as we bring our company’s first nanoparticle-based drug into the clinic in 2010.”
Dr Schnipper, said: “This is a tremendous opportunity to create a new class of therapeutics through the Medicinal Nanoengineering of both existing and new drugs.
“From my experience in developing drugs based on liposomes, I view Bind Biosciences’ targeted nanoparticle technology as an advance in developing the drugs using targeted therapeutics to increase efficacy and reduce toxicity.”